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EARLY PRODUCTION OF DONOR-DERIVED CD4 CD25 REGULA-
TORY T CELLS IN PATIENTS GIVEN HEMATOPOIETIC STEM CELL
TRANSPLANTS
Woodliff, J.1, Taylor, C.1, Douek, D.2, Margolis, D.1, Drobyski, W.1,
Johnson, B.1, Truitt, R.1 1. Departments of Pediatrics and Medicine,
Medical College of Wisconsin, Millwaukee, WI; 2. NIH Vaccine Re-
search Center, Bethesda, MD
In previous studies using murine models of BMT/DLI therapy,
we found that donor-BM-derived CD4 regulatory T cells (T-
REG) produced in the host thymus were responsible for suppres-
sion of DLI-associated GVHD. Based on our mouse data, we
hypothesized that failure of the host thymus to produce T-REG
cells after allogeneic BMT in humans would result in an increased
risk of GVHD after DLI therapy and an increased risk of chronic
GVHD. Here, we sought to identify, expand and functionally
characterize T-cells over time in patients given hematopoietic stem
cell transplants (HSCT). Peripheral blood (PB) was collected from
19 adult and 8 pediatric patients at 2, 4, 6 and 12 mo. post-
transplant. T-REG cells were identiﬁed by staining ﬁcoll-separated
PB cells for coexpression of CD4 and CD25. T-REG cells were
deﬁned phenotypically as CD4 cells with high levels of CD25
staining. 88% (22/25) of patients analyzed at 2 mo. had detectable
levels of CD4 CD25 cells. These cells persisted over time; only
two patients with detectable T-REG cells at 2 mo. lost them by 6
mo. Some, but not all, CD4 CD25 cells had high TREC levels
suggesting that they were recent thymic emigrants. We puriﬁed
CD4 CD25 cells and CD4 CD25- cells by cell sorting when
sufﬁcient PB was available and expanded them ex vivo using anti-
CD3/anti-CD28 conjugated Dynal beads and rIL-2. The ex-
panded CD4 CD25 cells were conﬁrmed as being of donor-
origin by VNTR analysis. Most were functional as shown by their
ability to suppress T cell proliferation when titrated into MLR
assays. Expanded CD4 CD25 cells from 5 of 8 patients sup-
pressed proliferation of T cells from the original HSC donor (i.e.,
autologous T cells) by 26-94% (R : T-REG  1:1). When donor
T cells were not available, unrelated T cells were used in the MLR
assays. Ex vivo expanded cells from 6 of 7 patients suppressed the
proliferation of the allogeneic responder T cells by 34-77% (R :
T-REG  1:1). Our results indicate that functional CD4
CD25 regulatory T cells of donor origin are present early after
HSCT in most patients. The patients, tissue source and histocom-
patibility of the HSCs used in this study were heterogeneous.
Determining whether the de novo generated T-REG cells are
sufﬁcient to mitigate GVHD will require a more homogeneous
patient group and longer follow-up. Adoptive transfer of T-REG
cells isolated from the HSCT donor and expanded ex vivo may be
necessary to more effectively modulate GVHD.
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LOW CIRCULATING DENDRITIC CELL COUNT AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION (SCT) PREDICTS DEATH, RELAPSE,
AND ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
Reddy, V.1, Iturraspe, J.A.2, Tzolas, A.C.1, Meier-Kriesche, H.-U.1,
Schold, J.1, Greene, S.1, Wingard, J.R.1 1. University of Florida,
Department of Medicine, Gainesville, FL; 2. Lifesouth Community
Blood Centers, Department of Flow Cytometry, Gainesville, FL
Dendritic cells (DC) are key antigen presenting cells, with a
potential role in tumor vaccines. We investigated the hypothesis
that early reconstitution of DC around the time of engraftment
after allogeneic SCT improves survival. We also correlated DC
reconstitution with complications of relapse and AGVHD. Fifty
patients were transplanted between February 2000 and March
2003 with a median follow up of 501 days (range 136-1263). Most
patients received blood stem cells (92%), and the remainder bone
marrow, from HLA matched sibling donors for predominantly
high risk hematologic malignancies. Around the time of sustained
neutrophil engraftment of 500 cells/mm3, peripheral blood was
analyzed by ﬂow cytometry for DC as lineage negative, HLA-DR
positive, and further divided as DC1 (CD11c) and DC2
(CD123). Patients were divided into two groups of either low
(n  23) or high (n  27) absolute DC count based on clustering
technique determination. Patients with lower DC count (4.97
cells/mm3) had a signiﬁcantly worse survival by Kaplan-Meier
analysis (p  0.009), increased incidence of relapse (p  0.002), a
higher incidence of AGVHD onset (p  0.0005) and a composite
end point of relapse or death (p  0.002). A Cox-proportional
Hazard multivariate model adjusted for important covariates con-
ﬁrmed that low DC count is independently associated with death
(HR 3.8; 95% CI 1.3, 11.3; p  0.02), time to relapse (HR 10.2;
95% CI 2.2, 47.2; p  0.003) and in the development of severe
AGVHD (HR  2.7; 95% CI 1.2, 6.4; p  0.02). The sensitivity
and speciﬁcity of low DC count in predicting death or relapse after
transplantation is 73% and 75% respectively with a positive pre-
dictive value (PPV) of 70% and negative predictive value (NPV) of
78%. To further delineate DC functionally, we studied DC1 and
DC2 phenotypes, and the failure rates remained higher in the low
cell count groups. In addition, DC recovery was independent of
DC infused or patient DC counts prior to transplant. Our data
suggest that, at least for peripheral blood SCT, the number of DC
in the graft has no impact while the numbers of DC ultimately
reconstituted in the recipient make the difference. In summary, our
ﬁndings are unique for describing an early easily reproducible
clinical indicator for adverse clinical outcomes such as relapse,
death, and AGVHD after hematopoietic SCT. This ﬁnding should
allow for early recognition of patients and studies for potential
therapeutic interventions.
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REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS RESULT IN
LOW PREVALENCE OF PREMATURE OVARIAN FAILURE (POF) IN
WOMEN UNDERWENT HEMATOPOIETIC STEM-CELL TRANSPLANTA-
TION (HST)
Cheng, Y.C., Saliba, R.M., Rondon, G., Giralt, S.A., Lu, K.H.,
Bodurka, D.C., Gershenson, D.M., Champlin, R.E., Ueno, N.T. The
University of Texas M. D. Anderson Cancer Center, Houston, TX
High-dose conditioning (HDC) regimens used for HST can
cause high incidence of POF among female transplant survivors.
POF results in uncomfortable postmenopausal symptoms and in-
fertility. In contrary, RIC regimens have resulted generally less
treatment-related toxicity and GVHD. Therefore, RIC regimens
are expected to have lower rate of POF in theory. However, the
actual prevalence is unknown. Of the 3,945 patients who under-
went HST between January 1987 and September 2001 at our
institution, 488 were female, aged 16–40 years at the transplant,
and had no history of breast or ovarian cancer. Of those patients,
413 (85%) had been given HDC regimens and 75 (15%) had been
given RIC regimens. Two hundred twelve patients (179 [43%] in
the HDC group and 33 [44%] in the RIC group) were alive at the
time of this cross-sectional study. Questionnaires on menstruation
history before and after HST were sent to 166 patients with
addresses on ﬁle; 89 (64%) of the 138 patients given HDC and 20
(71%) of the 28 given RIC replied. Age, disease status, and treat-
ment variables were statistically similar in patients who replied and
those who did not. Median follow-up among women who replied
was 75 months for the HDC group and 22 months for the RIC
group. Age, disease status, and treatment variables were also sta-
tistically similar in the HDC and RIC groups. Similar proportions
of women in each group (12 of 89 HDC and 4 of 20 RIC) reported
loss of ovarian function (deﬁned as loss of menstruation for 12
months or an FSH/LH level 20 IU/L) before HST. Ovarian
failure after HST was reported by 61 (79%) of those given HDC
vs. only 6 (37.5%) of those given RIC (P 0.007). Among patients
who retained their ovarian function after transplant, 4 in HDC and
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2 in RIC groups had successful pregnancy. Premature ovarian
failure is less common among patients given RIC regimens than
among those given HDC regimens for HST. Future prospective
study is justiﬁed to determine the overall incidence of POF and the
role of RIC regimens in lowering the treatment-related toxicity.
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TREATMENT OF PATIENTS (PTS) WITH CHEMOTHERAPY-REFRACTORY
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH NONMYELOABLATIVE
(NM) CONDITIONING AND HEMATOPOIETIC CELL TRANSPLANTATION
(HCT) FROM HLA-MATCHED RELATED (MRD) OR UNRELATED DONORS
(URD)
Sorror, M.L.1, Maris, M.B.1,2, Sandmaier, B.M.1,2, Jain-Stuart, M.4,
Storer, B.1,2, Hegenbart, U.5, McSweeney, P.6, Chauncey, T.3, Bruno,
B.7, Wade, J.8, Agura, E.9, Pulsipher, M.10, Leis, J.11, Little, M.-T.1,
Niederwieser, D.5, Blume, K.4, Storb, R.1,2, Maloney, D.G.1,2 1. Fred
Hutchinson Cancer Research Center; 2. University of Washington; 3.
and Seattle Veterans Administration Medical Center, Seattle, WA; 4.
Stanford University, Palo Alto, CA; 5. University of Leipzig, Leipzig,
Germany; 6. University of Colorado, Denver, CO; 7. University of
Torino, Torino, Italy; 8. Medical College Wisconsin, Milwaukee, WI; 9.
Baylor University, Dallas, TX; 10. University of Utah, Salt Lake City,
UT; 11. Oregon Health & Sciences University, Portland, OR
Pts with CLL refractory to ﬂudarabine (FLU)-based chemother-
apy have poor prognosis with a median survival of less than 1 year.
We examined the safety and efﬁcacy of NM-HCT for pts with
CLL refractory to at least 1 cytotoxic regimen and ineligible for
conventional allogeneic HCT due to age and/or comorbidities.
Forty-seven pts with diagnoses of CLL (n  42), small lympho-
cytic lymphoma (n  2), or prolymphocytic leukemia (n  3) were
treated with NM-HCT from MRD (n  33) and URD (n  14).
Median pt age was 58 (range 47-68) years (62% of pts 55 years).
Median number of prior regimens was 4 (range 1-12) with 94% of
pts refractory to at least 1 regimen. Thirty-six pts (77%) were
refractory to FLU, 19 to alkylating agents and 6 to rituxumab. Two
pts had prior autologous HCT. Nineteen pts (40%) had responsive
disease to salvage chemotherapy given prior to HCT [partial (PR)
(30%) or complete remission (CR) (10%)] while remaining pts
were either nonresponsive (51%) or in relapse (9%). Median in-
terval from diagnosis to HCT was 5 (0.6–25) years. Conditioning
consisted of 2 Gy TBI alone (n  19) or combined with FLU (n 
28), 90mg/m2 followed by mycophenolate mofetil and cyclosporine
immunosuppression. All pts received G-CSF mobilized peripheral
blood mononuclear cells as source of stem cells. After HCT, all pts
became neutropenic (median ANC nadir30 cells/ul) for a median
of 11 days. Eighteen pts never had platelet counts below 20,000
cells/ul. Three pts had graft rejection; 1 died with aplasia and 2 had
autologous recovery and are alive, 1 after multiple treatments and
1 relapsed at 2 years. Incidences of grades II, III, and IV acute
GVHD were 38%, 15%, and 2% respectively and chronic exten-
sive GVHD was estimated to be 48% at 4 years. With median
follow up of 32 (range 6-69) months, overall response rate was 57%
(CR  43%). Overall, 26 patients are alive; 14 in CR, 4 in PR, 4
with stable disease, and 4 with progressive disease (PD). Seven
patients died from PD, 9 from infectionsGVHD, 2 from cardiac
problems, 1 from multiorgan failure, 1 from metastatic lung can-
cer, and 1 from rejection and aplasia. Estimated 2-year rates of
non-relapse mortality, relapse-related mortality, progression free
survival, and overall survival (OS) were 29%, 15%, 49%, and 56%
respectively (Table 1). Projected 4-year OS was 47%. Conclusion:
NM-HCT provides powerful graft–versus–leukemia activity in
CLL and should be explored in phase II trials for treatment of pts
with FLU-refractory disease.
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ALLOGENEIC BONE MARROW TRANSPLANTATION (BMT) FOR THE
TREATMENT OF CHILDREN WITH VERY HIGH RISK ACUTE LYMPHO-
BLASTIC LEUKEMIA (ALL) IN FIRST REMISSION (CR1)
Boulad, F., Steinherz, P., Kernan, N.A., Small, T.N., Prasad, V.,
Prockop, S., Kolb, A., O’Reilly, R.J. Memorial Sloan-Kettering Cancer
Center, New York, NY
Children with very high risk ALL treated with chemotherapy
only have an expected disease-free survival of 20-40%, and are
therefore candidates for allogeneic BMT. Between August 1988
and January 2002, eighteen patients received an allogeneic BMT
for the treatment of very high risk ALL in CR1. They were 10
males and 8 females, aged 1.5–19.2 years (median 11.6). The very
high risk features of the patients were as follows: Unfavorable
cytogenetics with t(9;22) N  2, or infant with t(4;11) N  1; very
high white count at diagnosis (200,000/mm3) N 5; poor initial
response to induction chemotherapy [25% blasts on day 7 or
5% blasts on day 14 and/or day 28] N  10; hypodiploidy
N  2. Three patients had more than one very high-risk feature.
Patients received bone marrow from HLA-matched siblings
(N  9) or unrelated donors (N  9). Cytoreductive regimens
included: hyperfractionated total body irradiation (HF-TBI) 1,375
or 1,500 cGy and cyclophosphamide (CY) 60 mg/Kg/day 2 [N
6], or HF-TBI 1,375 or 1,500 cGy, Thiotepa (Thio) 5 mg/Kg/
day  2 and CY 60 mg/Kg/day  2 [N  10]. In addition two
patients received other regimens: busulfan and melphalan (N  1),
or HFTBI, Thio and etoposide (N  1). Graft-versus-host disease
(GvHD) prophylaxis included T-cell depleted grafts (N  10) or
unmodiﬁed grafts with cyclosporin  methotrexate or steroids
(N  8).
With a median follow-up of 4.7 years (range 1.5-14.7), the overall
survival and disease-free survival of the entire cohort were respec-
tively 84% and 83% respectively. Two patients relapsed 4.9 and 18
months post BMT and one patient died of an accidental death
(head trauma) 11.3 months post BMT. Two patients, both recip-
ients of unmodiﬁed grafts developed grade 2 GvHD that resolved.
In summary, the outcome of allogeneic BMT for children with
very high risk ALL in CR1 appears to be superior to that with
chemotherapy (reported as 20-40%). The use of hyperfractionated
TBI, Thio and CY followed by T-cell depleted grafts from related
or unrelated donors was associated with a very good outcome
(10/10 pts alive, disease-free) and no GvHD.
Table. CLL Patients Treated with NM Conditioning and HCT with
MRD and URD
MRD
(n  33)
URD
(n  14)
Acute GVHD grades II,
III, and IV
36%, 15%,
and 3%
43%, 14%,
and 0%
Two-year Chronic
extensive GVHD
44% 61%
Median follow-up (range) 37 (7-69)
months
19 (5-39)
months
Overall response rate
(CR)
55% (40%) 64% (50%)
Alive patients 7 CR, 2 PR,
4 stable,
3PD
7 CR, 2 PR,
1 PD
Two-year NRM 31% 23%
Two-year relapse-related
mortality
16% 8%
Two-year PFS 45% 62%
Two-year OS 53% 70%
NRM, non-relapse mortality; PFS, progression-free survival.
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